Broad-Based Q2 Growth Drives Bausch + Lomb's 2026 Guidance Raise
BLCO sits 27% above its 52-week low of $13.09.
Summary
Bausch + Lomb posted Q2 2026 revenue of $1.394B (+9% YoY), raised full-year guidance, and updated on the enVista Beyond IOL pivotal study.
Key Events · Earnings and Guidance · BLCO
-
Q2 Revenue Up 9% to $1.394B
Revenue rose 9% as reported (8% constant currency) to $1.394 billion, with Surgical up 19% and Pharmaceuticals up 15%.
-
Adjusted EBITDA Rises 26% to $241M
Driven by revenue growth and operating efficiencies, Adjusted EBITDA reached $241 million, up from $191 million in Q2 2025.
-
Full-Year Guidance Raised
2026 revenue guidance was lifted to $5.44B–$5.54B (from $5.42B–$5.52B), and Adjusted EBITDA ex-IPR&D to $1.025B–$1.075B (from $1.010B–$1.060B).
-
enVista Beyond IOL Study Update
The pivotal study met several co-primary endpoints but narrowly missed some predefined targets; the company will engage regulators on next steps.
Analysis · BLCO · Industrial Applications And Services
A strong second quarter saw revenue climb 9% to $1.394 billion, fueled by double-digit gains in Surgical and Pharmaceuticals. Adjusted EBITDA surged 26% to $241 million, prompting the company to lift its full-year revenue and profit outlook. While the enVista Beyond IOL pivotal study demonstrated clinically meaningful improvements, it narrowly missed some predefined endpoints—a measured note in an otherwise solid quarter.
At the time of this filing, BLCO was trading at $16.61 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $13.09 to $18.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.